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ABSTRACT
The disease burden of hepatitis C virus (HCV) is expected to more than double in the next
two decades. Currently, there is very little information about the costs of HCV treatment for
employers who pay for treatment and health plans that cover HCV patients. This study re-
ports the medical costs of HCV for workers with health insurance. A retrospective claims data
design was used for this study. A sample of HCV patients with health insurance was drawn
from the inpatient, outpatient, and enrollment files of the MEDSTAT Group’s MarketScan
family of databases for 1993–1998. Patients were grouped into cohorts and studied for up to
2 years before and after HCV diagnosis. Sample size varies according to length of follow-up,
peaking at 3,077 patients enrolled for at least 6 months. In the first year following HCV di-
agnosis, average payments for HCV patients ($10,925) were almost six times as high as pay-
ments for all patients in the MarketScan database ($1,186). Doctors are encouraged to test
high-risk patients to find HCV patients earlier in the course of their disease and to better
manage their care in order to avoid unnecessary illness and expenses for this disease.
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INTRODUCTION
HEPATITIS C VIRUS (HCV), a viral infectionleading to inflammation of the small bile
ducts of the liver,1 was first identified in 1989,
and the first assay was developed in 1992.2 Ac-
cording to the Centers for Disease Control and
Prevention (CDC), HCV is the most common
chronic blood-borne infection in the United
States,3 with current prevalence estimates of
approximately 2.7–4 million people infected.4–7
HCV may account for 40% of all chronic liver
disease, 20–30% of all liver transplants, and
8,000–10,000 deaths annually.7–9 Since 1991,
28,000–36,000 new cases of HCV have been un-
covered each year,7 the majority of which oc-
cur in people younger than 50 years of age.10
Although HCV infection can have serious
long-term consequences, its clinical course is
generally indolent and often takes years from
exposure to the clinical expression of symp-
toms.4,11 Typically, 20% of HCV-positive pa-
tients develop cirrhosis at 20 years after expo-
sure. The risk of developing liver cancer is
estimated at 1–5% at 20 years after exposure.7
However, once cirrhosis develops, the risk of
liver cancer increases 1–4% per year.7 Most
HCV-related deaths occur in patients who ac-
quired the disease 20–40 years earlier, which
indicates that people may have been exposed
through contaminated blood transfusions prior
to 1992. Therefore, the large cohort of HCV-
positive people infected between 1960 and 1992
will lead to an expected rise in the death rate
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of 25,000 to 30,000 deaths over the next two
decades.7 Consequently, the burden of disease
and death rate associated with HCV is expected
to more than double over the next two decades
as this large cohort of HCV-positive patients
progress to cirrhosis, cancer, and liver failure.7,10
This study examines the cost burden associ-
ated with HCV and HCV-related comorbidities
for patients with private health insurance. This
group is of primary interest to employers who
pay for health insurance and who stand to lose
the productivity-related contributions of em-
ployees infected with the virus. It is also of pri-
mary interest to health plans that must cover
the services needed to treat this condition.
The CDC has estimated the annual costs of
HCV to be about $600 million,12 but little is
known about the progress of HCV patients
over time and the associated cost burden.
Through a retrospective, descriptive analysis
using the MEDSTAT Group’s MarketScan®
databases, we estimate the cost of treating pri-
vate-pay, fee-for-service HCV patients. We fol-
low HCV patients to characterize their health
experience, hospitalizations, and health care
expenditures before and after their diagnosis
with HCV. The results of this study should
shed new light on the expenses related to the
management of HCV and whether improved




Data for this study were drawn from the
MEDSTAT Group’s MarketScan private pay
fee-for-service databases. The MarketScan
databases contain claim-level information
about the inpatient and outpatient health care
services used by patients covered in over 150
noncapitated benefit plans offered by large, pri-
marily Fortune 500, employers. The number 
of covered lives varied by year over our
1993–1998 study; in 1997, the last full year from
which HCV patients were selected, MarketScan
databases included data for about 2.5 million
continuously enrolled covered lives; these 
included active employees, early retirees, 
COBRA continuees, and their dependents.
Analytic file construction
The following diagnosis codes were used to
find HCV patients in the MarketScan® database
for 1993–1998: an ICD-9 diagnosis of HCV
(070.51) or a variation, HCV including hepatic
coma (070.41), carrier status (V02.54), chronic
HCV (070.54), or HCV with hepatic coma
(070.44). (Note: No patients in this study were
found with a diagnosis of carrier status,
V02.54.) To be included in the sample, indi-
viduals had to be continuously enrolled in their
health plan for a minimum of 6 months fol-
lowing their first-observed HCV diagnosis, and
they were followed for as long as the data al-
lowed before and after that date. The first ob-
served occurrence of HCV (referred to as the
“index date”) was between July 1, 1993 and
June 30, 1998 for each sample member, thereby
allowing for at least 6 months of investigation
before and after the index diagnosis date.
Once the sample of HCV patients was se-
lected, patients were grouped into cohorts
based on time since the first-observed diagno-
sis. In total, eight sample cohort groups were
created, each accounting for 6-month incre-
ments of time before and after the index date.
These cohorts included all of the patients with
experience: (1) 19–24 months before the index
date; (2) 13 –18 months before the index date;
(3) 7–12 months before the index date; (4) 0–6
months before the index date; (5) 0–6 months
after the index date; (6) 7–12 months after the
index date; (7) 13–18 months after the index
date; and (8) 19–24 months after the index date.
These groups were not mutually exclusive, and
some patients could be followed longer than
others. For example, some (but not all) of the
patients followed for 6–12 months before the
index date could also be followed for 13–18
months before the index date.
After finding HCV-diagnosed patients who
met the inclusion criteria, patients were ex-
cluded if they were diagnosed with conditions
that are contraindicated for HCV treatment.
Specifically, patients with depression, current
infertility treatment, active chemical depen-
dency, severe renal impairment, hemoglobin-
aphathies (thalassemia, sickle-cell anemia), and
a history of significant or unstable cardiac dis-
ease were excluded, as were pregnant women.
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Next, variables were constructed to measure
the demographic and clinical characteristics of
HCV patients. The demographic variables were
derived directly from the patient eligibility files
(e.g., age, gender, relationship to employee),
while the clinical characteristics were based on
the patients’ ICD-9 codes in the claims data.
Over the study period, patients’ primary diag-
noses from inpatient and outpatient claims
were counted. These codes were then grouped
into major diagnostic categories (MDCs) de-
veloped by Fetter et al.13 to characterize the ma-
jor body systems affected by disease.
There are 25 possible MDCs; together these ac-
count for the 15,000 or so possible ICD-9 diag-
nosis codes. Most MDCs relate to a particular or-
gan or body system (e.g., MDC 2 5 diseases and
disorders of the eye; MDC 7 5 diseases and dis-
orders of the hepatobiliary system and pancreas),
but some span multiple body systems (e.g., MDC
25 5 HIV infections). The average number of
MDCs per patient was calculated for each 6-
month interval, as a way of noting the extent of
the health problems faced by HCV patients. The
average number of physician visits per 6 months
was also calculated. The MDCs and physician
encounters served as crude indicators of the ex-
tent of patients’ illnesses and the need for out-
patient care.
Next, HCV comorbidities were identified and
compared over time to enhance the description
of disease severity. Comorbidities were identi-
fied on the basis of ICD-9 codes. The distribution
of comorbidities in the 12 months before the in-
dex HCV diagnosis was compared to the distri-
bution of comorbidities occurring during the 12
months following the index event, using a chi-
squared test of independence. The analysis of co-
morbidities was also used to determine whether
there were any HCV treatment-specific reduc-
tions in comorbidities observed posttreatment,
and whether there were certain diagnoses that
predicted the onset of HCV. Finally, we esti-
mated the proportion of patients who developed
complications related to HCV (e.g., liver disease)
following their diagnosis.
Expenditure data were analyzed in 6-month
intervals. Expenditures included claims dollars
paid by the insurance plan and copayments
and deductibles paid by HCV patients. All ex-
penditure data were converted to year-2000
dollars using an index based on the Bureau of
Labor Statistics’ Gross Domestic Product Im-
plicit Price Deflator.14 Total payments were cal-
culated as the sum of inpatient and outpatient
payments. The primary diagnosis on the claim
was used to classify payments into one of three
categories: (1) payments for services when
HCV was the primary diagnosis; (2) payments
for services when an HCV-related diagnosis
(but not HCV itself) was primary (see Appen-
dix 1 for a list of HCV-related diagnoses); or (3)
payments for services when another diagnosis
was primary and HCV was secondary. These
groupings of payments were used to explain
the cost-drivers for HCV treatment (i.e., which
category of claims accounted for most of the ex-
penditures related to HCV care).
Expenditures were calculated on a per-capita
basis. Per capita payments were derived by di-
viding expenditures for HCV patients by the
number of patients in the entire sample, re-
gardless of whether any inpatient or outpatient
services were used. Per capita expenditures are
often considered useful by health plan actuar-
ies and others, because all categories of care are
viewed across the same denominator of pa-
tients, allowing clear estimation of the share of
treatment dollars going toward inpatient vs.
outpatient care.
To compare the difference between patients
with HCV and all patients in the MarketScan
database, mean HCV inpatient, outpatient, and
total expenditures were contrasted to mean ex-
penditures in each category for the entire Mar-
ketScan database in 1997 (the last full year of
experience). The MarketScan data provide a
reference point for health care expenditures in-
curred by a large patient population in a non-
capitated health insurance environment. The
HCV-MarketScan comparison therefore pro-
vides a useful way of viewing the relative im-
portance of HCV, at least in dollar terms.
RESULTS
Demographic and clinical characteristics 
of HCV patients
A total of 3,077 patients were found for this
study. Demographic characteristics at the time
of the index HCV diagnosis are presented in
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Table 1. More than half (58%) of the sample was
male and the average age was 45 years old. The
greatest proportion (32%) of patients (n 5 977)
was first observed with HCV in 1997. Sixty-
four percent of the patients were primary ben-
eficiaries (i.e., employees as opposed to de-
pendants or spouses). Wage information was
not available for the entire sample; about 29%
were known to be hourly workers, and about
25% were salaried. Wage information for the
rest was either unknown or unavailable be-
cause not all patients were employed. About
25% of the sample members were unionized
employees. The greatest concentration of sam-
ple members were associated with major pol-
icy holders from the durable goods manufac-
turing industry (31%), and about 22% more
were associated with workers in government
jobs.
As one moved away from the index date, the
size of the sample decreased, as noted in Table
2 (which also presents expenditure results that
will be described later). The sample declined
over time as individual workers changed em-
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TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF HCV PATIENTS AT INDEX DIAGNOSIS DATE (n 5 3,077)




Age (mean and SD), years 45.01 10.17

























Unknown wage type 1,430 46.47%
Unionized 777 25.25%
Industry of employment of major policy holder
Oil and gas extraction, mining 107 3.48%
Manufacturing, durable goods 954 31.00%
Manufacturing, nondurable goods 246 7.99%
Transportation, communications, utilities 283 9.20%
Retail trade 33 1.07%




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Time of index hepatitis C diagnosis
—
—
ployers or were no longer covered by their em-
ployer’s health insurance for reasons unrelated
to their health. In addition, patients exited the
database as they moved further away in time
from their index date, perhaps because they be-
came too ill to work and eventually lost their
insurance coverage or died. It is also possible
that some patients responded to treatment and
therefore incurred no future health care claims.
The number of patients in these categories is
unknown.
Health indicators
Some basic proxies for health status were es-
tablished by counting the number of ICD-9 di-
agnoses at the three-digit level, the number of
MDC groupings represented by the diagnoses
on the patients’ claims, and the number of physi-
cian visits. The assumption underlying this ap-
proach is that the more illnesses identified
through various ICD-9 codes and the more body
systems affected by the patient’s diseases, the
“sicker” the patient and more complex his/her
disease pattern is to treat. As shown in Table 3,
the number of ICD-9 codes, MDCs, and physi-
cian visits increased over time from 24 months
before the index diagnosis (5.76, 2.98, and 2.90,
respectively), to peak within 6 months postdi-
agnosis (at 8.67, 4.12, and 5.01, respectively).
These numbers then decreased over time to 6.85
ICD-9 codes, 3.45 MDCs, and 3.45 physician vis-
its, respectively, at 24 months after the index di-
agnosis. Although decreasing over time after the
index HCV diagnosis, the levels at 24 months
postdiagnosis were higher than the levels at 24
months preindex diagnosis.
These crude health status proxies suggest
that HCV patients were most ill during the 6
months immediately after the index HCV di-
agnosis. If HCV diagnosis tends to occur after
the onset of disease, these trends might indi-
cate that diagnosis tends to be made relatively
late in the course of illness. More information
on the pattern of diagnoses and comorbidities
is provided below.
Comorbidities associated with HCV
For the comorbidity analysis, we examined all
additional diagnoses for the twelve months be-
fore and after HCV diagnosis. As shown in
Table 4, before the HCV diagnosis, the five di-
agnoses occurring with the greatest frequency
were: other noncongenital liver disorders (34%),
abdomen and pelvis symptoms (27%), chronic
liver disease and cirrhosis (26%), special inves-
tigations and exams—a general term that may
indicate the search for problems like HCV (26%),
and respiratory and other chest symptoms
(21%). The percentages refer to how many indi-
viduals in our sample had at least one diagno-
sis for the above conditions during the 12
months preceding HCV diagnosis. During the
12 months following HCV diagnosis, signifi-
cantly more patients were diagnosed with other
non-congenital liver disorders (42%, p, 0.001)
and chronic liver disease and cirrhosis (37%, p ,
0.001). As noted in Table 4, all 10 most frequent
comorbidities experienced by HCV patients
were significantly more prevalent among HCV
patients than among patients in the 1997 Mar-
ketScan database.
Expenditure results
Table 2 presents the average expenditures for
HCV patients in 6-month increments preced-
ing and following their diagnosis of HCV. As
shown, average per capita expenditures rose
steadily from $2,850 in the 19–24 months be-
fore the index HCV diagnosis to $4,594 in the
6 months immediately preceding the index
date. For the 24-month period before an HCV
diagnosis was observed, total annual per capita
expenditures for HCV patients averaged
$6,945. Trends in median expenditures were
similar, but medians for inpatient care were of-
ten zero, since most patients were not hospi-
talized.
Following the index diagnosis, total per
capita expenditures averaged $6,290 in the first
6 months past the index date. Thereafter, ex-
penditures steadily declined, averaging $3,939
for the 19–24-month period following HCV di-
agnosis. For the entire 24 months following the
index HCV diagnosis, total annual per capita
expenditures for HCV patients averaged
$10,110. Expenditures were roughly evenly di-
vided between inpatient and outpatient ser-
vices before the index diagnosis, but after the
index HCV diagnosis inpatient expenditures
increased as a proportion of total expenditures.
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Comparison to MarketScan norms
In comparison to MarketScan norms, total
per capita payments for HCV patients in the
first year following HCV diagnosis were al-
most six times as high as payments for all Mar-
ketScan patients in 1997 ($10,925 vs. $1,886). In-
patient costs for HCV patients were almost
eight times as high ($5,312 vs. $676), and out-
patient costs were almost 4.5 times as high as
the overall MarketScan average ($5,614 vs.
$1,210).
Examining “other medical costs”
Most of the expenditures for HCV patients
were associated with claims for medical condi-
tions other than HCV or its most common, re-
lated comorbidities. This was not surprising to
us, since similar patterns have been found for
other diseases, such as asthma and diabetes15
and depression.16 Moreover, one might suspect
that treating such problems among an HCV
population would be more difficult than treat-
ing the same problems among patients who do
not have HCV, but addressing this issue was
beyond the scope of our descriptive study.
To understand why the “other” cost category
is the largest cost driver, we went back to the
data to find the most prevalent and costly di-
agnoses for problems other than HCV that
were first-listed on patients’ medical claims in-
curred during the 12 months after the index
HCV diagnosis. Not surprisingly, the list of
“other” diagnoses we found was very similar
to the list of comorbid conditions reported in
Table 4. (The lists are not identical, because
Table 4 pertains to all diagnoses, not just to the
subset of diagnoses whose other, non-HCV,
conditions were first-listed on the claims.)
Specifically, the top five most frequent, first-
listed, non-HCV diagnoses in the 12-month pe-
riod after the index HCV diagnosis was made
included: hepatitis not otherwise specified
(ICD-9 code 573.3, n 5 635 patients), chronic
hepatitis not otherwise specified (ICD-9 code
571.40, n 5 374 patients), laboratory examina-
tions (ICD-9 code v72.6, n 5 260), abnormal
liver function studies (ICD-9 code 794.8, n 5
241 patients), and essential hypertension not
otherwise specified (ICD-9 code 401.9, n 5
202).
It is interesting that most of these conditions
are for liver problems that can easily be con-
fused with HCV. In fact, seven of the top 10
most prevalent conditions were liver-related,
as were nine of the top 30. (Details are avail-
able upon request.) Given the difficulties in-
volved in making an HCV diagnosis and the
fact the HCV can lead to other serious compli-
cations, this pattern seems reasonable, and it
may strengthen the case for HCV screening
among patients with these problems, as noted
later.
DISCUSSION
Employers and health plans are faced with a
wide range of diseases affecting their work-
force and plan members. Increasingly, treat-
ment decisions require reliable financial data
regarding the cost burden of these diseases, so
intelligent choices can be made concerning al-
ternative treatment options. One health condi-
tion that is becoming more common and costly
to treat is HCV, whose prevalence now exceeds
that of HIV infection.
It should be noted that HCV patients un-
dergo a variety of diagnostic and therapeutic
procedures that may include liver biopsy, treat-
ment with interferon-based medication, treat-
ment of the complications of liver failure, and
liver transplantation. Some diagnosed with
HCV may receive little or just palliative care.
In our analysis, all patients with a diagnosis of
HCV were examined regardless of treatment
choice. Although liver transplantation is rela-
tively uncommon among HCV patients, it is
worth noting that HCV is now the most preva-
lent indication for liver transplantation in the
United States.17
We estimated the cost burden of HCV to em-
ployers and attempted to understand the de-
mographic, treatment, and cost profile of those
who suffer from the disease. We found that the
cost burden of HCV patients with health in-
surance is substantial, peaking during the 6
months immediately following the first-ob-
served HCV diagnosis. Coupled with a de-
creasing sample size as one moves away from
the index date, this cost pattern could be due
to the selection of patients relatively late in
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their course of illness, with some patients dy-
ing and other leaving employment as time
moves on. Alternatively, the cost pattern could
be due to some early success with treatment,
negating the need for more expensive care later
on.
Overall, for the 24-month period preceding
HCV diagnosis, HCV patients cost employers
an average of $6,945 per year. For the 24-month
period following diagnosis, their average an-
nual cost was $10,110. Much (but not most) of
the expense appears to be associated with the
consequences of HCV (i.e., liver disease and
cirrhosis), suggesting that earlier testing and
treatment might be able to pre-empt some of
these illnesses and associated expenditures.
Once the HCV cost burden is better under-
stood, employers and health plans might be in-
terested in the available screening, testing, and
treatment options and the cost-effectiveness of
these options. Screening for HCV can be done
via enzyme-linked immunoassay test for the
HCV antibody, but this is not completely reli-
able, so it should be coupled with surveys de-
signed to collect information on behavioral risk
factors for the disease or the likely occurrence of
occupational exposure to HCV.18 Confirmation
of the presence of HCV may involve several pro-
cedures, but usually focuses on the presence of
HCV RNA in serum and a recent, known expo-
sure to the virus, or seroconversion to positivity
for antibodies to HCV.19 Treatments for man-
aging hepatitis include clinical monitoring of en-
zyme levels, interferon and combination ther-
apy treatments, and finally liver transplantation.
Additionally, many patients need medical man-
agement of HCV comorbidities.
Treatment with interferon alone costs ap-
proximately $2,150 for a 6-month course, while
the combination with ribavirin raises the costs
to approximately $8,600 for an average course
of combination treatment.20,21 Typical courses
of treatment run either 6 or 12 months and, if
successful, result in normalizing enzyme levels
by eradicating the virus, improving liver his-
tology, and ameliorating patients’ clinical
symptoms. This occurs in approximately 15%
of patients on interferon monotherapy and ap-
proximately 43% of patients treated with Re-
betron combination therapy.22 Recently, a new
treatment for HCV (peginterferon alfa-2b) has
been approved by the Food and Drug Admin-
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istration. It has increased efficacy and an im-
proved dosing profile in comparison to avail-
able treatment options.23
The cost-effectiveness of HCV treatment will
depend upon the treatment modality chosen,
and on the likelihood of incurring problems
like cirrhosis of the liver or the need for a liver
transplant (among others), in the presence and
absence of treatment. Recent pharmacoeco-
nomic studies demonstrate the cost-effective-
ness of interferon treatment, but not all studies
reach the same conclusion. A computer simu-
lation cohort model study by Wong concluded
that interferon treatment is cost-saving and re-
duces lifetime medical expenditures. Savings
were derived from reductions in lifetime med-
ical costs averaging $6,300–$6,900 for each pa-
tient treated with interferon.24 A cost-effective-
ness analysis using clinical trial data and
published studies of HCV patients who were
treatment-naive found that, over an average
lifetime, immediate antiviral therapy was cost-
effective compared with biopsy management,
producing a net savings of $7,000 relative to no
antiviral therapy.25 Overall, these researchers
emphasize that treatment of HCV in its earlier
stages is more likely to lead to higher costsav-
ings and longer life expectancy.
A different conclusion about the cost-effec-
tiveness of HCV treatment was reached by Ba-
tra,26 who found that HCV screening and drug
treatment for those who test positive for HCV
is more costly than treating patients with liver
transplantation. Thus, for the relatively few
HCV patients who would require a liver trans-
plant, the socially optimal approach would be
to wait for this need to occur and then provide
the transplant. Setting aside any other objec-
tions that might be raised with this approach,
it is worth noting that Batra’s study was per-
formed in Great Britain, where the cost of liver
transplantation is only about one-sixth to one-
eighth the average cost in the United States.
Adjusting for this alone would be enough to
reverse his conclusions.
In addition to conducting cost-effectiveness
analyses, several researchers have explored the
impact of chronic or recurrent HCV on quality
of life, functional status, and depression. Sev-
eral studies have shown that treatment with in-
terferon increases life expectancy and improves
quality of life.7 A meta-analysis of five prospec-
tive trials further supports these findings.25
Wong et al.27 examined the cost-effectiveness
of retreatment with combination therapy ver-
sus interferon alone for patients who relapsed
after initial interferon treatment. They found
that Rebetron combination therapy prolonged
life expectancy while increasing costs modestly
in comparison to monotherapy.
Our focus has been on medical expenditures
borne by the patient and the payer, and this
leads to two important limitations. First, no in-
formation was available on the productivity
impact of HCV, so the cost burden we esti-
mated is conservative. It does not count days
lost from work due to absenteeism or short-
term disability program use, nor does it ac-
count for lapses in productivity while at work
that may be caused by HCV. The latter is re-
ferred to as “presenteeism” in the health and
productivity management literature.28
Second, since HCV may take 20–30 years to
cause cirrhosis and other liver problems, and
since the virus can be silent for long periods be-
fore any symptoms emerge, we have probably
undercounted its prevalence. Whether we have
also undercounted its cost burden depends
upon whether any health care use prior to di-
agnosis for those we missed was due to HCV.
We suspect the dollars have been under-
counted as well, but there is no way to check
for this with administrative claims data.
Another limitation might arise from the way
we selected patients for this study. We focused
on those who may be eligible for treatment (i.e.,
those with no known contraindications to treat-
ment). We did this because the focus of this
study is on the cost burden to those who pay
for care—primarily patients and insurance
plans or employers, and because doctors and
health plans might consider testing for HCV
primarily among those who could benefit from
treatment. (Testing those with contraindica-
tions for treatment might seem like a waste of
resources, unless there is net benefit in the
knowledge that one has a disease that cannot
be treated.) An unstated assumption that read-
ers might make is that all patients without con-
traindications would be treated once diag-
nosed, but the literature suggests that many
patients decline treatment for HCV.26 We at-
tempted to avoid this problem by counting dol-
lars for health care received by HCV patients,
regardless of whether HCV was the “primary”
or first-listed diagnosis on the medical claim.
Thus, treatment for other conditions that may
be complicated by the presence of HCV was
counted in this study.
Next, we should note that pharmaceutical ex-
penditures were excluded from the study, be-
cause pharmaceutical claims were not available
for most patients and few pharmaceutical in-
terventions were available in the early 1990s,
when some of our patients were found. Nev-
ertheless, treatment for HCV is expensive, and
the cost-burden of illness has been understated
for the first year following diagnosis, when
HCV drug treatment would be offered.
CONCLUSION
Our analysis has demonstrated a noteworthy
cost burden associated with HCV. We found
that the average medical expenditures associ-
ated with having an HCV diagnosis peak early
after the first-observed diagnosis, but that di-
agnosis may come relatively late in the disease,
leading to high costs. More specifically, inpa-
tient and outpatient costs averaged over
$10,000 per year in the first two years follow-
ing diagnosis.
Armed with these data, employers and
health plans can better justify effective preven-
tion and treatment efforts directed at HCV.
Koff29 argues that disease management pro-
grams for hepatitis C should be developed and
should focus on reducing unhealthy high-risk
behavior by educating the uninfected, promot-
ing healthier behavior such as the avoidance of
alcohol in those infected, screening those at
high risk with early confirmation of diagnosis,
and then initiating appropriate and effective
treatment regimens. We support this notion.
With regard to screening, we agree that pa-
tients with known HCV-related comorbidities
such as cirrhosis or chronic liver disease should
be tested, in an effort to find HCV earlier and
preclude some of the illness and expenditures
associated with it. However, screening and
testing must be voluntary and confidential, di-
rectly involving only the patient and the doc-
tor. Health plans or employers may pay for
these services, but the system for payment
must still promote confidentiality while pro-
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viding incentives for proper treatment (or no
treatment, as the patients’ best interests re-
quire).
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APPENDIX 1: HCV-RELATED DIAGNOSES
155.0 Primary malignant neoplasm of liver (hepatocellular carcinoma)
245.2 Autoimmune thyroiditis
273.2 Cryoglobulinemia
277.1 Porphyria cutanea tarda
284.8 Aplastic anemia, other specified type
284.9 Aplastic anemia, unspecified
370.07 Mooren’s (corneal) ulcer
446.0 Polyarteritis nodosa
456.20 Esophageal varices in diseases NED with hemorrhage
516.3 Pulmonary fibrosis (Hamman-Rich syndrome)
570 Acute and subacute necrosis of liver
571.5 Cirrhosis of liver without mention of alcohol
571.8 Other chronic nonalcoholic liver disease
571.9 Unspecified chronic liver disease without mention of alcohol




572.4 Kidney failure associated with liver disease
572.8 Other sequelae of chronic liver disease (e.g., hemorrhage, fulminant)
573.0 Chronic passive congestion of liver
573.4 Hepatic infarction
573.8 Other specified disorders of liver (e.g., hemorrhage)
573.9 Unspecified disorder of liver
580.81 Acute glomerulonephritis in diseases NEC (e.g., hepatitis)
581.1 Nephrotic syndrome with lesion of membranous glomerulonephritis
581.2 Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis
582.1 Chronic glomerulonephritis with lesion of membranous glomerulonephritis
582.2 Chronic glomerulonephritis with lesion of proliferative glomerulonephritis
583.1 Nephritis NEC with lesion of membranous glomerulonephritis
583.2 Nephritis NEC with lesion of membranoproliferative glomerulonephritis
584.x Acute renal (kidney) failure
585 Chronic renal failure










V02.62 Viral hepatitis C carrier
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